Latest Intelligence

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
NewsWire
NewsWire

Merck receives European authorization to extend use of phenylketonuria drug

Merck Serono has received marketing authorization from the European Commission, or EC, for extended use of its product, Kuvan, in children with phenylketonuria, or PKU, below four years of age who have been shown to be responsive to such treatment.

Published By MarketLine
24 Jul 2015
NewsWire
NewsWire

JCR Pharmaceuticals and Eisai sign feasibility study agreement

JCR Pharmaceuticals Co., Ltd., a biopharmaceutical company, and Eisai Co., Ltd. have signed a feasibility study agreement, under which they will examine the possibility of applying JCR's proprietary blood-brain-barrier, or BBB, penetration technology, J-Brain Cargo, to the discovery of new treatments.

Published By MarketLine
24 Jul 2015
NewsWire
NewsWire

AUVA selects electronic health record from Cerner

The Allgemeine Unfallversicherungsanstalt, or AUVA, has selected Cerner Millennium electronic health record for its seven emergency hospitals and four rehabilitation centers.

Published By MarketLine
24 Jul 2015
NewsWire
NewsWire

Abbott receives FDA approval for iDesign System for Lasik vision treatment

Abbott Laboratories has received FDA approval for the iDesign Advanced WaveScan Studio System for Lasik vision treatment.

Published By MarketLine
24 Jul 2015
NewsWire
NewsWire

C2N Diagnostics and AbbVie receive FDA orphan drug designation for PSP drug

C2N Diagnostics and AbbVie Inc., a biopharmaceutical company, have received orphan drug designation from the FDA for their investigational recombinant humanized anti-tau antibody, C2N-8E12, for the treatment of progressive supranuclear palsy, or PSP.

Published By MarketLine
24 Jul 2015
NewsWire
NewsWire

Baxter initiates voluntary recall of two lots of intravenous solutions

Baxter International Inc. has initiated a voluntary recall of two lots of intravenous, or IV, solutions to the hospital/user level due to the potential presence of particulate matter.

Published By MarketLine
24 Jul 2015
NewsWire
NewsWire

Alnylam initiates Phase III TTR-mediated amyloidosis study

Alnylam Pharmaceuticals, Inc., a biotechnology company, has initiated a Phase III open-label extension study, APOLLO-OLE, with patisiran, an investigational RNAi therapeutic targeting transthyretin, or TTR, for the treatment of TTR-mediated amyloidosis, or ATTR amyloidosis, in patients with familial amyloidotic polyneuropthy, or FAP.

Published By MarketLine
24 Jul 2015
NewsWire
NewsWire

Celgene to supply romidepsin for Bionor's Phase II HIV study

Bionor Pharma ASA, a biotechnology company, has signed an agreement with Celgene Corporation, a biopharmaceutical company, to supply romidepsin for use in a planned multicenter clinical Phase II HIV study of Bionor's proprietary vaccine, Vacc-4x, with romidepsin.

Published By MarketLine
24 Jul 2015
NewsWire
NewsWire

Nuffield Health and MSP plan to open diagnostic suite at Citylabs in UK

Nuffield Health, in partnership with Manchester Science Partnerships, or MSP, has announced its plan to open a diagnostic suite at Citylabs on Oxford Road in November.

Published By MarketLine
24 Jul 2015
NewsWire
NewsWire

Agenus signs licensing agreement with Diatheva for CEACAM1 antibodies

Agenus Inc., a biotechnology company, has signed a licensing agreement with Diatheva s.r.l. for antibodies targeting Carcinoembryonic antigen cell adhesion molecule 1, or CEACAM1, a glycoprotein expressed on T cell and NK cell lymphocytes.

Published By MarketLine
24 Jul 2015

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.